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In response to stress, cells activate so-called checkpoints – complex
signaling pathways that induce a plethora of cellular outcomes.
Checkpoints primarily initiate cell cycle arrest to provide the cell
with time to repair the damage. However, if the damage is too
severe then cells can permanently arrest the cell cycle (senescence)
or trigger cell death, thereby preventing the transmission of genetic
defects. These responses are pivotal for tumor suppression as all
of these outcomes result in restriction of the growth and/or elimi-
nation of damaged and pre-malignant cells. Thus, a large number
of anti-cancer agents target specific components of stress response
signaling pathways with the aim of causing tumor regression by
stimulating cell death or at least stopping cell growth. However,
the efficacy of these agents is often impaired by mutations in
genes that are involved in stress-responsive signaling pathways.
Moreover, these cancer-specific genetic defects often contribute to
resistance against chemotherapeutic agents and/or radiotherapy.
Modulating the outcome of cellular stress responses toward cell
death in tumor cells without affecting surrounding normal cells
is thus one of the ultimate aims in the development of new can-
cer therapeutics. To achieve this aim, a detailed understanding of
cellular stress response pathways and their aberrations in cancer is
required.
The Research Topic titled “Molecular mechanisms of cellular
stress responses in cancer and their therapeutic implications” fea-
tures 11 articles that reflect the broadness and complexity of the
processes induced by cellular stress. It begins with reviews on four
different proteins/protein families that are critical for cellular stress
responses and as such are important for both cancer development
and the response to cytotoxic therapies.
Knippschild and colleagues discuss the complex functions of
the casein kinase 1 (CK1) family and describe in depth how mem-
bers of this family regulate signaling cascades that are relevant for
the pathogenesis of inflammatory and proliferative diseases and,
beyond this, for neurodegenerative disorders as well. They also
summarize current knowledge on therapeutic modulation of CK1
activity and existing inhibitors (1).
In addition to phosphorylation, other post-translational mod-
ifications are an effective means to modify the activity of cellular
proteins and hence respond to stress signals. Polonio-Valon et al.
focus on the peptidyl-prolyl cis/trans isomerase Pin1, an enzyme
that can induce conformational changes in its substrate proteins.
In their article, they highlight the interactions of Pin1 with key
proteins relevant to cancer and cancer therapy and discuss how
Pin1 specifies cell fate decision in response to DNA damage (2).
One of the key proteins in cellular stress signaling is the tumor
suppressor p53 and any collection of articles dealing with stress
responses would be incomplete without an article on p53. Mueller
and colleagues give a brief overview on the extensive literature on
p53 and its family members, p63 and p73 with a specific focus on
therapeutic implications (3).
Parker et al. discuss another well known protein family, the
tubulins and their interacting partners. Tubulins are the building
blocks of microtubules and therefore responsible for cell move-
ment, intracellular trafficking, and cell division. They are also the
target of a specific class of chemotherapeutics. As this article points
out, microtubules and associated proteins play an important role
in a range of cellular stress responses (4).
Understanding cellular processes that are differentially reg-
ulated in cancerous versus normal cells is a prerequisite for
exploiting them therapeutically. Three articles focus on this aspect.
A hallmark of cancer as a proliferative disorder is the increased
number of cell divisions and a high mitotic index. Mitotic cells
respond differently to stress signals than interphase cells due to
their condensed chromosomes. Burgess and colleagues review the
pathways and outcomes activated by mitotic cells in response to
stress and describe how this influences efficacy of chemotherapeu-
tic drugs, especially those in the anti-mitotic class (5).
Abnormal DNA content is another common hallmark of cancer
cells that has been recognized for a long time. In their hypothesis
and theory article, Coward and Harding summarize evidence that
links the acquisition of multiple chromosome copies (polyploidy)
to tumor evolution and chemotherapy resistance. They argue that
these polyploid cells themselves are critical drug targets (6).
Double-strand breaks are also prevalent in many cancer cells
due to their increased proliferation and impaired DNA repair
programs. Jekimovs et al. review the two DNA repair pathways
activated by DNA double-strand-breaks and discuss the successes
and failures of pre-clinical and clinical trials aiming to modulate
these pathways (7).
Finally, four articles highlight some of the many factors that
influence the success of cancer therapy with cytotoxic agents.
One of the most challenging problems is tumor heterogeneity, a
topic discussed by Renovanz and Kim who argue that there is much
to learn to be able to treat cancer patients more effectively (8).
Tumor hypoxia is another problematic aspect in many solid
tumors as this has been linked to resistance against radiation and
chemotherapy. In their original research article, Ontikatze and
colleagues characterize a specific drug, dihydroartemisinin, that
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may be instrumental in overcoming therapy resistance of hypoxic
tumors (9).
Hormones can also affect the response to cytotoxic agents and
this seems particularly obvious for estrogen. Caldon describes
the complicated relationship of estrogen and DNA damage sig-
naling in breast cancer and proposes that estrogen receptor sig-
naling suppresses effective DNA repair and apoptosis in favor of
proliferation (10).
Breast cancer is also the focus of the original article by Quante
and colleagues who report new insights into the process leading
to hyperplastic lesions in the mammary gland obtained from the
analysis of a transgenic mouse model (11).
This collection of articles highlights some of the advances made
in understanding the molecular mechanisms of cellular stress
responses and the implications of this for cancer biology. Research
in this field has already enabled improved clinical outcomes for
cancer patients and we are hopeful that with continued investi-
gation of this topic more discoveries will be translated into even
better cancer treatments.
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